guest ::
| Home > Publications database > Utilization of the microbiome in personalized medicine. > print |
| 001 | 286608 | ||
| 005 | 20240419160101.0 | ||
| 024 | 7 | _ | |a 10.1038/s41579-023-00998-9 |2 doi |
| 024 | 7 | _ | |a pmid:38110694 |2 pmid |
| 024 | 7 | _ | |a 1740-1526 |2 ISSN |
| 024 | 7 | _ | |a 1740-1534 |2 ISSN |
| 024 | 7 | _ | |a altmetric:157571904 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02820 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Ratiner, Karina |0 0000-0002-3458-5604 |b 0 |
| 245 | _ | _ | |a Utilization of the microbiome in personalized medicine. |
| 260 | _ | _ | |a Basingstoke |c 2024 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1713535236_19206 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:F220# / 2024 May;22(5):291-308 |
| 520 | _ | _ | |a Inter-individual human variability, driven by various genetic and environmental factors, complicates the ability to develop effective population-based early disease detection, treatment and prognostic assessment. The microbiome, consisting of diverse microorganism communities including viruses, bacteria, fungi and eukaryotes colonizing human body surfaces, has recently been identified as a contributor to inter-individual variation, through its person-specific signatures. As such, the microbiome may modulate disease manifestations, even among individuals with similar genetic disease susceptibility risks. Information stored within microbiomes may therefore enable early detection and prognostic assessment of disease in at-risk populations, whereas microbiome modulation may constitute an effective and safe treatment tailored to the individual. In this Review, we explore recent advances in the application of microbiome data in precision medicine across a growing number of human diseases. We also discuss the challenges, limitations and prospects of analysing microbiome data for personalized patient care. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Ciocan, Dragos |b 1 |
| 700 | 1 | _ | |a Abdeen, Suhaib K |0 0009-0008-6787-1069 |b 2 |
| 700 | 1 | _ | |a Elinav, Eran |0 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |b 3 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41579-023-00998-9 |0 PERI:(DE-600)2121463-3 |n 5 |p 291-308 |t Nature reviews / Microbiology |v 22 |y 2024 |x 1740-1526 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:286608 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-25 |w ger |
| 915 | _ | _ | |a DEAL Nature |0 StatID:(DE-HGF)3003 |2 StatID |d 2023-10-25 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT REV MICROBIOL : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 80 |0 StatID:(DE-HGF)9980 |2 StatID |b NAT REV MICROBIOL : 2022 |d 2023-10-25 |
| 920 | 2 | _ | |0 I:(DE-He78)F220-20160331 |k F220 |l Mikrobiom und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F220-20160331 |k F220 |l Mikrobiom und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D480-20160331 |k D480 |l Mikrobiom und Krebs |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F220-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D480-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|